---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-26-002252"
form_type: "8-K"
ticker: "QTZM"
cik: "0001663038"
company_name: "Quantum Genesis AI Corp."
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:07:27.295026+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Quantum Genesis AI confirms CEO assignment of ibuprofen synthesis patent

## Summary
- CEO Naveen Kulkarni assigned all rights in US Patent App. US20250146029A1 for enzymatic ibuprofen synthesis to the company.
- Assignment effective as of Nov. 2, 2023, formalizing a prior 2023 Asset Purchase Agreement.
- Company will amend FY2025 10-K and FY2026 Q1 & Q2 10-Qs to update IP disclosures.
- No new consideration; agreement confirms existing ownership.

## SEC filing metadata
- accession: 0001477932-26-002252
- form_type: 8-K
- ticker: QTZM
- cik: 0001663038
- company_name: Quantum Genesis AI Corp.
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1663038/000147793226002252/0001477932-26-002252-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1663038/000147793226002252/qtzm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-26-002252
- JSON: https://secwatch.observer/filing/0001477932-26-002252.json
- Plain text: https://secwatch.observer/filing/0001477932-26-002252.txt

## Source-grounded claims
- claim_id: b2134c66af41984660c5e29b30215624ba617933
  claim: Quantum Genesis AI Corp. entered into Intellectual Property Assignment Agreement with Naveen Kulkarni (effective 2026-04-09).
  evidence_excerpt: On April 9, 2026, Quantum Genesis AI Corp. (the “Company”) entered into a confirmatory Intellectual Property Assignment Agreement (the “Assignment Agreement”) with Naveen Kulkarni, the Company’s Chief Executive Officer (the “Assignor”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1663038/000147793226002252/0001477932-26-002252-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.